Medigene is a biotechnology company that is developing highly innovative, complementary treatment platforms to target various types and stages of cancer. They focus on the development of personalised T cell-based immunotherapies.

Collaboration with 2A Pharma
2A Pharma is developing the AAVLP technology, which was part of a former Medigene research project. The AAVLP technology is originally discovered and developed at Medigene AG by John Nieland, Markus Hörer, and Hildegard Büning. 2A pharma has now inlicensed the AAVLP technology from Medigene.